By Motolani AbdulGafar
As vaccination continues in Ejigbo, a medical doctor, Wasiu Adelodun has explained that the prevalence of malaria among symptoms of COVID-19 patients is one of the reasons for introducing malaria drugs into the treatment of the pandemic.
According to him, in the case of treating malaria, a 2021 vaccine; RTS,S, with the brand name Mosquirix has been approved to prevent the disease.
Adelodun counselled that the vaccine treatment requires the intake of four injections with low efficacy.
He noted that people who grow up in a risk area do develop some level of immunity and are less likely to contract malaria as they grow older meanwhile the disease can be contracted more than once by a patient.
He said malaria affects the skeletal muscle system leading to symptoms such as muscle aches, muscle contractures, muscle fatigue, muscle pain, and muscle weakness and can also cause parasitic coronary artery occlusion.
He said his essence of revealing the complexity of the disease is a result of the nonchalant attitude of residents in keeping their environment clean and visiting health care centres after contacting the disease as they see it as a recurrent phenomenon that does not need fretting about.
He, therefore, urged residents to take the illness seriously as it can get worse very quickly and become fatal if not treated very quickly.
